A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Summary

The purpose of this study is to evaluate the safety of FCX-007, evaluate Type VII collagen (COL7) expression and the presence of anchoring fibrils and to analyze wound healing as a result of FCX-007 administration in subjects with recessive dystrophic epidermolysis bullosa (RDEB). Funding Source- FDA OOPD

Timeline

Start

2016-07-01

Primary completion

2020-09-29

Completion

2022-04-18

Outcome

Outcome not reported

Stopped: “Subjects were all in Long-Term Follow Up and were transferred to the ongoing EB-002 study”

Drugs

Indications